- Home
- NIPG vs INMB Comparison
NIPG vs INMB Comparison
Compare NIPG & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIPG
- INMB
- Stock Information
- Founded
- NIPG 2014
- INMB 2015
- Country
- NIPG Sweden
- INMB United States
- Employees
- NIPG N/A
- INMB N/A
- Industry
- NIPG
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- NIPG
- INMB Health Care
- Exchange
- NIPG NYSE
- INMB Nasdaq
- Market Cap
- NIPG 163.1M
- INMB 176.5M
- IPO Year
- NIPG 2024
- INMB 2019
- Fundamental
- Price
- NIPG $1.70
- INMB $7.32
- Analyst Decision
- NIPG Strong Buy
- INMB Strong Buy
- Analyst Count
- NIPG 1
- INMB 3
- Target Price
- NIPG $12.00
- INMB $24.33
- AVG Volume (30 Days)
- NIPG 153.9K
- INMB 272.9K
- Earning Date
- NIPG 05-15-2025
- INMB 05-08-2025
- Dividend Yield
- NIPG N/A
- INMB N/A
- EPS Growth
- NIPG N/A
- INMB N/A
- EPS
- NIPG N/A
- INMB N/A
- Revenue
- NIPG $84,449,477.00
- INMB $14,000.00
- Revenue This Year
- NIPG $7.65
- INMB N/A
- Revenue Next Year
- NIPG $14.38
- INMB N/A
- P/E Ratio
- NIPG N/A
- INMB N/A
- Revenue Growth
- NIPG 6.07
- INMB N/A
- 52 Week Low
- NIPG $0.99
- INMB $4.32
- 52 Week High
- NIPG $17.76
- INMB $12.72
- Technical
- Relative Strength Index (RSI)
- NIPG N/A
- INMB 46.72
- Support Level
- NIPG N/A
- INMB $7.14
- Resistance Level
- NIPG N/A
- INMB $7.78
- Average True Range (ATR)
- NIPG 0.00
- INMB 0.71
- MACD
- NIPG 0.00
- INMB 0.00
- Stochastic Oscillator
- NIPG 0.00
- INMB 54.59
About NIPG NIP GROUP INC SPON ADS EACH REPR 2 CL A ORD SHS
NIP Group Inc is a esports organization with operations across Asia, Europe and South America. It operate two esports brands: Ninjas in Pyjamas and eStar Gaming. Ninjas in Pyjamas, is a PC or console esports brand. eStar Gaming, is a mobile esports brand. The company has two reportable segments, including PRC and other entities, and Ninjas in Pyjamas. Key revenue is generated from PRC and other entities.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.